amega 3

Solarvest Completes Development of the World's First Organic Omega-3 Shots

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - October 20 th 2021  Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSX-V:SVS), is pleased to report, that its wholly owned subsidiary Eversea TM Inc. has completed a suite of unique Organic Omega-3 shots.  The functional shots market is expected to grow at 16% per year to 1.4 billion in 2027 according to Research and Markets*. The company's convenient 60 ml. shots are formulated to supplement the essential daily Omega-3 requirement with added organic ingredients.  For example, Stamina includes ingredients that are known to dilate blood vessels, an effect that may lower blood pressure and increase exercise time to task failure.  Recover includes ingredients that, in addition to Omega-3, are known to reduce inflammation.  The market goes beyond the professional athlete seeking a competitive boost to anyone wishing to enhance their workout and manage the resulting inflammation.  The vision customer is expected to be anyone that experiences blue light toxicity and screen fatigue, common in our screen heavy work environments.


Click Image To View Full Size

Similar to the well know energy shots on the market, the products will be packaged and recommended for point of purchase convenience in natural and health food stores.  The company will also immediately offer the line to premium exercise chains in China, Brazil and the USA.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully developed, patented and produced the world's only plant-based organic certified Omega-3 to satisfy the substantial demand for this essential nutrient.  The company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

* https://www.globenewswire.com/news-release/2021/06/28/2253640/28124/en/1-4-Billion-Global-Functional-Shots-Market-2021-to-2027-by-Product-Distribution-Channel-and-Region.html

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)

FDA APPROVES IMDELLTRA , THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday May 20, 2024 following the presentation of new data from TEZSPIRE ® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, and other members of the Amgen team will participate. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Nutura Organic Ltd – Term Sheet to commence Pilot Study

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company has entered into a legally binding Term Sheet (Term Sheet) with Australian-based company Nutura Organic Ltd (Nutura) for the purchase of adult milk formula to enable the Company to undertake a pilot study in China.

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate's extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona's anti-aging ingredient, GlycoProteMimTM, to effectively assess and demonstrate its market potential within the global anti-aging skincare industry.

About Sirona Biochem Corp.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.

"With many of our innovative products delivering strong growth and promising new medicines advancing through our pipeline, we are excited about delivering attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×